Online inquiry

IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9102MR)

This product GTTS-WQ9102MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&PMEL gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_001200053.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6490
UniProt ID P07766; P40967
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9102MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15807MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ11504MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ7461MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ9427MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ5666MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ1324MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ6125MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ3011MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW